Chronic dizocilpine or apomorphine and development of neuropathy in two rat models I

Behavioral effects and role of nucleus accumbens

Rani Sarkis, Nayef Saadé, Samir Atweh, Suhayl Jabbur, Hassen Al Amin

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Dopaminergic and glutamatergic inputs converge on nucleus accumbens (NAC) and affect the neuropathic pain. We tested the effects of daily systemic administration of dizocilpine (MK-801), a N-methyl- d-Aspartate (NMDA) noncompetitive receptor antagonist, or apomorphine (APO), a dopamine (DA) D1 and D2 receptor agonist, on neuropathic manifestations in the chronic constriction injury (CCI) and the spared nerve injury (SNI) models of mononeuropathy in rats. Six groups of rats were subjected to CCI or SNI neuropathy and 5-7 days later received daily intraperitoneal (ip) injections of saline, MK-801, or APO for two weeks. Tests for nociception and motor behaviors were performed at regular intervals. Tactile and cold allodynia were assessed using von Frey hairs or acetone drops, respectively. Heat hyperalgesia was assessed by the paw withdrawal test. Tests were performed before administering the daily injections. Another four groups of rats were subjected to SNI surgery, and then had their NAC (contralateral to the lesioned paw) perfused for two weeks with MK-801, saline, APO. +. ascorbic acid, or ascorbic acid alone using mini-osmotic pumps. Behavioral manifestations were assessed as above. Systemic daily injections of MK-801 and APO markedly attenuated the neuropathic manifestations in the CCI and SNI models with a minimal effect on cold allodynia. The same results were seen in the SNI model with chronic perfusion of NAC. Our results suggest that daily systemic administration of DA agonists and NMDA antagonists can attenuate neuropathic pain manifestations and that the NAC is involved in the modulation of neuropathic-like behaviors.

Original languageEnglish
Pages (from-to)19-29
Number of pages11
JournalExperimental Neurology
Volume228
Issue number1
DOIs
Publication statusPublished - Mar 2011

Fingerprint

Dizocilpine Maleate
Apomorphine
Nucleus Accumbens
Wounds and Injuries
Hyperalgesia
Constriction
Neuralgia
Ascorbic Acid
Mononeuropathies
Dopamine D1 Receptors
Injections
Dopamine D2 Receptors
Dopamine Agonists
Pain Measurement
Acetone
Intraperitoneal Injections
Aspartic Acid
Hair
Perfusion
Hot Temperature

Keywords

  • Dopamine
  • Glutamate
  • Neuropathic pain
  • Neuropathy
  • Nucleus accumbens

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience

Cite this

Chronic dizocilpine or apomorphine and development of neuropathy in two rat models I : Behavioral effects and role of nucleus accumbens. / Sarkis, Rani; Saadé, Nayef; Atweh, Samir; Jabbur, Suhayl; Al Amin, Hassen.

In: Experimental Neurology, Vol. 228, No. 1, 03.2011, p. 19-29.

Research output: Contribution to journalArticle

@article{ed18ee8636de4d77a06c874d1bf59f47,
title = "Chronic dizocilpine or apomorphine and development of neuropathy in two rat models I: Behavioral effects and role of nucleus accumbens",
abstract = "Dopaminergic and glutamatergic inputs converge on nucleus accumbens (NAC) and affect the neuropathic pain. We tested the effects of daily systemic administration of dizocilpine (MK-801), a N-methyl- d-Aspartate (NMDA) noncompetitive receptor antagonist, or apomorphine (APO), a dopamine (DA) D1 and D2 receptor agonist, on neuropathic manifestations in the chronic constriction injury (CCI) and the spared nerve injury (SNI) models of mononeuropathy in rats. Six groups of rats were subjected to CCI or SNI neuropathy and 5-7 days later received daily intraperitoneal (ip) injections of saline, MK-801, or APO for two weeks. Tests for nociception and motor behaviors were performed at regular intervals. Tactile and cold allodynia were assessed using von Frey hairs or acetone drops, respectively. Heat hyperalgesia was assessed by the paw withdrawal test. Tests were performed before administering the daily injections. Another four groups of rats were subjected to SNI surgery, and then had their NAC (contralateral to the lesioned paw) perfused for two weeks with MK-801, saline, APO. +. ascorbic acid, or ascorbic acid alone using mini-osmotic pumps. Behavioral manifestations were assessed as above. Systemic daily injections of MK-801 and APO markedly attenuated the neuropathic manifestations in the CCI and SNI models with a minimal effect on cold allodynia. The same results were seen in the SNI model with chronic perfusion of NAC. Our results suggest that daily systemic administration of DA agonists and NMDA antagonists can attenuate neuropathic pain manifestations and that the NAC is involved in the modulation of neuropathic-like behaviors.",
keywords = "Dopamine, Glutamate, Neuropathic pain, Neuropathy, Nucleus accumbens",
author = "Rani Sarkis and Nayef Saad{\'e} and Samir Atweh and Suhayl Jabbur and {Al Amin}, Hassen",
year = "2011",
month = "3",
doi = "10.1016/j.expneurol.2010.12.004",
language = "English",
volume = "228",
pages = "19--29",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Chronic dizocilpine or apomorphine and development of neuropathy in two rat models I

T2 - Behavioral effects and role of nucleus accumbens

AU - Sarkis, Rani

AU - Saadé, Nayef

AU - Atweh, Samir

AU - Jabbur, Suhayl

AU - Al Amin, Hassen

PY - 2011/3

Y1 - 2011/3

N2 - Dopaminergic and glutamatergic inputs converge on nucleus accumbens (NAC) and affect the neuropathic pain. We tested the effects of daily systemic administration of dizocilpine (MK-801), a N-methyl- d-Aspartate (NMDA) noncompetitive receptor antagonist, or apomorphine (APO), a dopamine (DA) D1 and D2 receptor agonist, on neuropathic manifestations in the chronic constriction injury (CCI) and the spared nerve injury (SNI) models of mononeuropathy in rats. Six groups of rats were subjected to CCI or SNI neuropathy and 5-7 days later received daily intraperitoneal (ip) injections of saline, MK-801, or APO for two weeks. Tests for nociception and motor behaviors were performed at regular intervals. Tactile and cold allodynia were assessed using von Frey hairs or acetone drops, respectively. Heat hyperalgesia was assessed by the paw withdrawal test. Tests were performed before administering the daily injections. Another four groups of rats were subjected to SNI surgery, and then had their NAC (contralateral to the lesioned paw) perfused for two weeks with MK-801, saline, APO. +. ascorbic acid, or ascorbic acid alone using mini-osmotic pumps. Behavioral manifestations were assessed as above. Systemic daily injections of MK-801 and APO markedly attenuated the neuropathic manifestations in the CCI and SNI models with a minimal effect on cold allodynia. The same results were seen in the SNI model with chronic perfusion of NAC. Our results suggest that daily systemic administration of DA agonists and NMDA antagonists can attenuate neuropathic pain manifestations and that the NAC is involved in the modulation of neuropathic-like behaviors.

AB - Dopaminergic and glutamatergic inputs converge on nucleus accumbens (NAC) and affect the neuropathic pain. We tested the effects of daily systemic administration of dizocilpine (MK-801), a N-methyl- d-Aspartate (NMDA) noncompetitive receptor antagonist, or apomorphine (APO), a dopamine (DA) D1 and D2 receptor agonist, on neuropathic manifestations in the chronic constriction injury (CCI) and the spared nerve injury (SNI) models of mononeuropathy in rats. Six groups of rats were subjected to CCI or SNI neuropathy and 5-7 days later received daily intraperitoneal (ip) injections of saline, MK-801, or APO for two weeks. Tests for nociception and motor behaviors were performed at regular intervals. Tactile and cold allodynia were assessed using von Frey hairs or acetone drops, respectively. Heat hyperalgesia was assessed by the paw withdrawal test. Tests were performed before administering the daily injections. Another four groups of rats were subjected to SNI surgery, and then had their NAC (contralateral to the lesioned paw) perfused for two weeks with MK-801, saline, APO. +. ascorbic acid, or ascorbic acid alone using mini-osmotic pumps. Behavioral manifestations were assessed as above. Systemic daily injections of MK-801 and APO markedly attenuated the neuropathic manifestations in the CCI and SNI models with a minimal effect on cold allodynia. The same results were seen in the SNI model with chronic perfusion of NAC. Our results suggest that daily systemic administration of DA agonists and NMDA antagonists can attenuate neuropathic pain manifestations and that the NAC is involved in the modulation of neuropathic-like behaviors.

KW - Dopamine

KW - Glutamate

KW - Neuropathic pain

KW - Neuropathy

KW - Nucleus accumbens

UR - http://www.scopus.com/inward/record.url?scp=79851511592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79851511592&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2010.12.004

DO - 10.1016/j.expneurol.2010.12.004

M3 - Article

VL - 228

SP - 19

EP - 29

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - 1

ER -